Amneal Pharmaceuticals just smashed Q2 earnings with revenue up nearly 10% YoY to $796 million and a higher-than-expected profit per share — even as the market stayed calm. Growth is driven by strong demand for transdermal patches, complex generics, and branded hits like CREXONT and BREKIYA. Leadership is bullish on pipeline wins and recent approvals, while big moves ahead include acquiring Kashiv Biosciences to dominate biosimilars and scaling manufacturing for high-value women’s health products — positioning Amneal for explosive future growth.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
